Incyte (INCY) Tops Q2 EPS by 6c; Raises Jakafi Sales Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Incyte Reports 2015 Second-Quarter Financial Results and Updates Shareholders on Key Clinical Programs
August 4, 2015 7:00 AM EDT$142 million of 2015 second-quarter net product revenues from Jakafi® (ruxolitinib), representing 69 percent growth over the same period last year 2015 guidance for Jakafi net product revenues increased to range of $560 million to $575 million, driven by strong underlying demand Positive results from two pivotal trials of baricitinib in rheumatoid arthritis presented at EULAR Multiple abstracts presented at ASCO and EHA, demonstrating continued progress across broad clinical portfolio
Conference Call and Webcast Scheduled Today at 10:00 a.m. ET
... More
